Identification
Instrument name
LYSOGENE
Symbol
LYS
ISIN code
FR0013233475
Exchange / Market
Euronext
Trading location
Paris
Products family
Stocks
Capitalization compartment
Compartment C
ICB
Biotechnology
Operation
IPO date
IPO price
EUR 6.80
IPO type
Initial Public offering
Catégorie
IPO
Price range
EUR 6.80 - EUR 9.20

Company profile

Lysogene is a biotechnology company specializing in the research and development of gene therapies for the treatment of rare neurodegenerative diseases. The company now has 2 drug candidates in clinical development of which 1 in phase II/III (LYS-SAF302 for the treatment of Sanfilippo syndrome type A) and 1 in phase I/II (LYS-GM101 for the treatment of GM1 gangliosidosis).

Source: Cofisem - Last Update: 11 Aug 2020
Key Executives
Chairman and Chief Executive Officer Karen Pignet-Aiach
Administrative & Finance Director Stéphane Durant des Aulnois
Source: Cofisem - Last Update: 11 May 2020
Key figures
Millenium 2019 2018 2017 2016 2015
Net sales 13,373 3,590 0
Income from ordinary activities 13,373 3,590 0 1,375 344
Operating income -5,083 -10,955 -17,216 -7,289 -3,855
Cost of financial indebtedness net
Equity-accounted companies contribution to income
Net profit from discontinued activities
Net income -4,282 -10,925 -17,794 -7,484 -3,757
Net income (Group share) -4,282 -10,925 -17,794 -7,484 -3,757
Fiscal year end 12.19 12.18 12.17 12.16 12.15
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 11 Aug 2020
Shareholder information
Sofinnova 21.68 %
OrbiMed Partners Master Fund Limited 12.08 %
Bpifrance Investissement 8.83 %
Novo Holdings A/S 8.31 %
Sarepta International Holdings B.V. 6.96 %
KGA SAS 6.12 %
OrbiMed Genesis Master Fund, L.P. 3.43 %
The Goldman Sachs Group, Inc. 1.28 %
Source: Cofisem - Last Update: 11 May 2020